SPRB Spruce Biosciences Inc
Price (delayed)
$0.293
Market cap
$12.1M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.94
Enterprise value
-$45M
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product candidate,
Highlights
Spruce Biosciences's debt has decreased by 39% YoY and by 14% QoQ
SPRB's EPS is up by 37% year-on-year and by 9% since the previous quarter
SPRB's equity is down by 40% year-on-year and by 13% since the previous quarter
Spruce Biosciences's gross profit has decreased by 26% QoQ
Key stats
What are the main financial stats of SPRB
Market
Valuations
Earnings
Shares outstanding
41.3M
Market cap
$12.1M
Enterprise value
-$45M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.23
Price to sales (P/S)
1.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-6.34
Revenue
$7.1M
Gross profit
$7.1M
Operating income
-$43.24M
Net income
-$39.43M
EBIT
-$41.92M
EBITDA
-$41.63M
Free cash flow
-$46.5M
Per share
Balance sheet
Liquidity
EPS
-$0.94
EPS diluted
-$0.94
Free cash flow per share
-$1.13
Book value per share
$1.25
Revenue per share
$0.17
TBVPS
$1.58
Total assets
$65.1M
Total liabilities
$13.46M
Debt
$2.96M
Equity
$51.64M
Working capital
$51.72M
Debt to equity
0.06
Current ratio
5.36
Quick ratio
5.06
Net debt/EBITDA
1.37
Margins
Efficiency
Dividend
EBITDA margin
-586.2%
Gross margin
100%
Net margin
-555.2%
Operating margin
-608.9%
Return on assets
-47.5%
Return on equity
-62.1%
Return on invested capital
N/A
Return on capital employed
-78.7%
Return on sales
-590.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SPRB stock price
How has the Spruce Biosciences stock price performed over time
Intraday
9.21%
1 week
-8.15%
1 month
-24.68%
1 year
-65.49%
YTD
-30.24%
QTD
1%
Financial performance
How have Spruce Biosciences's revenue and profit performed over time
Revenue
$7.1M
Gross profit
$7.1M
Operating income
-$43.24M
Net income
-$39.43M
Gross margin
100%
Net margin
-555.2%
Spruce Biosciences's gross profit has decreased by 26% QoQ
The revenue has contracted by 26% from the previous quarter
The company's operating margin fell by 23% QoQ but it rose by 17% YoY
Spruce Biosciences's net margin has decreased by 23% QoQ but it has increased by 19% YoY
Growth
What is Spruce Biosciences's growth rate over time
Valuation
What is Spruce Biosciences stock price valuation
P/E
N/A
P/B
0.23
P/S
1.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-6.34
SPRB's EPS is up by 37% year-on-year and by 9% since the previous quarter
The stock's price to book (P/B) is 81% less than its 5-year quarterly average of 1.1 and 70% less than its last 4 quarters average of 0.7
SPRB's equity is down by 40% year-on-year and by 13% since the previous quarter
The P/S is 68% less than the last 4 quarters average of 4.8
The revenue has contracted by 26% from the previous quarter
Efficiency
How efficient is Spruce Biosciences business performance
SPRB's return on sales is down by 22% since the previous quarter but it is up by 18% year-on-year
The return on equity has declined by 13% year-on-year and by 3.7% since the previous quarter
SPRB's return on assets is down by 12% year-on-year and by 4.6% since the previous quarter
Dividends
What is SPRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SPRB.
Financial health
How did Spruce Biosciences financials performed over time
The company's total liabilities has shrunk by 51% YoY and by 18% QoQ
Spruce Biosciences's total assets has decreased by 42% YoY and by 14% from the previous quarter
Spruce Biosciences's debt is 94% lower than its equity
SPRB's equity is down by 40% year-on-year and by 13% since the previous quarter
Spruce Biosciences's debt has decreased by 39% YoY and by 14% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.